Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-38.1%-3.9pp-34.2%-4.2pp-30%-2.6pp-27.4%+2.9pp-30.3%+4.1pp
Return on assets-36.2%-3.9pp-32.3%-3.6pp-28.7%-2.4pp-26.3%+2.7pp-29%+3.4pp
Return on invested capital-47.1%-3.9pp-43.1%-5.6pp-37.5%-3.3pp-34.2%+3.9pp-38%+10.1pp
Liquidity
Current ratio22.6×+2.8×19.9×-6.7×26.5×-2.4×28.9×+7.9×21×+1.1×
Quick ratio22.6×+2.8×19.9×-6.7×26.5×-2.4×28.9×+7.9×21×+1.1×
Cash ratio1.5×-0.8×2.2×+0.1×2.1×0.0×2.1×-0.3×2.4×+0.6×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$4.60-9.3%$5.07-4.2%$5.30-5.7%$5.61+24.3%$4.52-9.1%
Valuation
Market capitalization$3.38B+28.6%$2.63B+53.7%$1.71B+10.1%$1.55B-25.9%$2.09B-17.2%
Enterprise value$3.35B+30.3%$2.57B+54.2%$1.67B+10.2%$1.51B-26.2%$2.05B-17.7%
Price / book6.9×+1.8×+2.0×3.1×+0.4×2.6×-2.2×4.9×-0.6×
Free cash flow yield-4.4%+1.1pp-5.5%+2.3pp-7.8%+0.3pp-8.1%-2.4pp-5.7%-1.3pp
Earnings yield-5.2%+1.2pp-6.4%+2.8pp-9.2%+0.5pp-9.7%-2.7pp-7%-1.7pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Edgewise Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Edgewise Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.